{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:45:13Z","timestamp":1776779113717,"version":"3.51.2"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To conduct a comprehensive comparison of the efficacy, safety, and cost-effectiveness of denosumab versus zoledronic acid in patients with bone metastases from solid tumors and multiple myeloma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of PubMed, Web of Science, Embase, and major Chinese databases was performed for studies published up to 30 September 2025. Eligible evidence included randomized controlled trials, cohort studies, and pharmacoeconomic analyses. Random-effects models were applied for quantitative synthesis. The certainty of evidence for key outcomes was assessed using the GRADE framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-one studies were included. Moderate-certainty evidence indicates that denosumab likely delays the time to first skeletal-related event (SRE) (HR = 0.85, 95% CI: 0.79\u20130.93) and time to first and subsequent SREs (HR = 0.86, 95% CI: 0.76\u20130.97) relative to zoledronic acid. Subgroup analyses demonstrated that this benefit is pronounced in solid tumors but not observed in multiple myeloma. For survival outcomes, moderate-certainty evidence suggests little to no difference in overall survival (HR = 0.97, P = 0.49) or progression-free survival (HR = 0.99, P = 0.86). Low-certainty evidence suggests that denosumab may reduce the risk of any adverse events (OR = 0.70, P = 0.04) and nephrotoxicity (OR = 0.65, P = 0.02). Pharmacoeconomic evaluations revealed marked geographic heterogeneity: denosumab was generally cost-effective in high-income settings with higher willingness-to-pay thresholds, whereas in resource-limited regions, zoledronic acid remained the more economically favorable option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Denosumab probably confers superior protection against SREs in patients with solid tumors and demonstrates a potentially improved renal safety profile compared with zoledronic acid. However, its cost-effectiveness varies substantially across healthcare systems and is strongly shaped by regional pricing structures and willingness-to-pay thresholds. Clinical adoption should therefore consider tumor biology, safety characteristics, and local economic capacity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251020691.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1747354","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:02:06Z","timestamp":1767682926000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy, safety and economy of denosumab and zoledronic acid in the treatment of bone metastases of solid tumors and multiple myeloma: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Li","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuening","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zefeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luqin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res: an Off J Am Assoc Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12885-017-3922-0","article-title":"Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States","volume":"18","author":"Hernandez","year":"2018","journal-title":"BMC Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.100960","article-title":"New insights into non-small cell lung cancer bone metastasis: mechanisms and therapies","volume":"20","author":"Xue","year":"2024","journal-title":"Int J Biol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12761","article-title":"Mechanisms of bone destruction in multiple myeloma","volume":"26","author":"Terpos","year":"2017","journal-title":"Eur J Cancer Care"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a031252","article-title":"The biology of bone metastasis","volume":"8","author":"Esposito","year":"2018","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2217\/fon.12.76","article-title":"The multifaceted actions of PTHrP in skeletal metastasis","volume":"8","author":"Soki","year":"2012","journal-title":"Future Oncol (London England)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO Clinical Practice Guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030388","article-title":"Denosumab vs. Zoledronic acid for metastatic bone disease: A comprehensive systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Wajda","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.6402","article-title":"Role of bone-modifying agents in multiple myeloma: American society of clinical oncology clinical practice guideline update","volume":"36","author":"Anderson","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2013the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.03.034","article-title":"Inhibition of the RANK\/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer","volume":"397","author":"Takayama","year":"2017","journal-title":"Cancer Lett"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet (London England)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PloS Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Clinical Res ed)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.13105\/wjma.v5.i4.80","article-title":"Assessing the quality of studies in meta-analyse advantages and limitations of the Newcastle Ottawa Scale","volume":"5","author":"Luchini C","year":"2017","journal-title":"World J Meta Anal"},{"key":"B18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: A report of the ISPOR CHEERS II good practices task force","volume":"25","author":"Husereau","year":"2022","journal-title":"Value ealth: J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104502","article-title":"Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4\/6 inhibitors","volume":"82","author":"Scafetta","year":"2025","journal-title":"Breast (Edinburgh Scotland)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5132\u20139","DOI":"10.1200\/JCO.2010.29.7101","article-title":"A comparison of denosumab versus zoledronic acid for the prevention of skeletal-related events in breast cancer patients with bone metastases","volume":"28","author":"Stopeck","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds175","article-title":"Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid","volume":"23","author":"Vadhan-Raj","year":"2012","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-8351.2024.05.037","article-title":"Comparison of efficacy and safety of denosumab versus zoledronic acid in the treatment of breast cancer bone metastases","volume":"21","author":"He","year":"2024","journal-title":"Bei Fang Yao Xue"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.2095-0616.2022.17.044","article-title":"Clinical effects of denosumab versus zoledronic acid in the treatment of prostate cancer bone metastases","volume":"12","author":"He","year":"2022","journal-title":"Zhongguo Yi Yao Ke Xue"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.13267\/j.cnki.syzlzz.2024.080","article-title":"Efficacy and safety of denosumab versus zoledronic acid in breast cancer bone metastases: a propensity score-matched cohort study","volume":"39","author":"Huang","year":"2024","journal-title":"Shi Yong Zhong Liu Za Zhi"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.12677\/ACM.2023.134750","article-title":"Denosumab versus zoledronic acid in the treatment of prostate cancer bone metastases","volume":"13","author":"Zhang","year":"2023","journal-title":"Lin Chuang Yi Xue Jin Zhan"},{"key":"B28","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/13696998.2017.1328423","article-title":"Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic","volume":"20","author":"Cristino","year":"2017","journal-title":"J Med Econ"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2012-000235","article-title":"Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland","volume":"20","author":"Lothgren","year":"2013","journal-title":"Eur J Hosp Pharmacy: Sci Pract"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1445634","article-title":"A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America","volume":"21","author":"Raje","year":"2018","journal-title":"J Med Econ"},{"key":"B31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3111\/13696998.2012.719054","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis","volume":"16","author":"Snedecor","year":"2013","journal-title":"J Med Econ"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.675380","article-title":"Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States","volume":"15","author":"Stopeck","year":"2012","journal-title":"J Med Econ"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1606002","article-title":"A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy","volume":"22","author":"Terpos","year":"2019","journal-title":"J Med Econ"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/go.23.00396","article-title":"Cost-effectiveness analysis of denosumab in the prevention of skeletal-related events among patients with breast cancer with bone metastasis in India","volume":"10","author":"Wadhwa","year":"2024","journal-title":"JCO Global Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2012.04.001","article-title":"Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases","volume":"12","author":"Xie","year":"2012","journal-title":"Clin Breast Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2011.17.8.621","article-title":"Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases","volume":"17","author":"Xie","year":"2011","journal-title":"J Managed Care Pharmacy: JMCP"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.13748\/j.cnki.issn1007-7693.20242185","article-title":"Pharmacoeconomic evaluation of denosumab versus zoledronic acid for prevention of skeletal-related events in patients with multiple myeloma","volume":"42","author":"Chen","year":"2025","journal-title":"Chin J Mod Appl Pharm"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.19450\/j.cnki.jcrh.2022.05.005","article-title":"Cost-utility analysis of denosumab versus zoledronic acid in the treatment of bone metastases from solid tumors","volume":"9","author":"Li","year":"2022","journal-title":"J Chin Res Hosp"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286484","article-title":"A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma","volume":"110","author":"Anloague","year":"2025","journal-title":"Haematologica"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2020)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in Multiple Myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.973836","article-title":"Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche","volume":"12","author":"Solimando","year":"2022","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1747354\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:02:10Z","timestamp":1767682930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1747354\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":46,"alternative-id":["10.3389\/fonc.2025.1747354"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1747354","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"article-number":"1747354"}}